Skip to main content

Table 2 Objective response in 40 patients

From: Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma

Response

No. of patients

%

Complete response *

2

5

Partial response *

17

42.5

Stable disease *

13

32.5

Progressive disease

8

20

  1. * Disease control: 80%
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us